Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARVN Arvinas	$7.42 -0.3%	$7.55	$5.90 ▼ $29.61	$543.06M	2.22	1.84 million shs	1.47 million shs
CTNM Contineum Therapeutics	$5.96 +1.0%	$4.40	$3.35 ▼ $20.55	$152.64M	1.01	299,417 shs	262,492 shs
RZLT Rezolute	$5.87 -1.3%	$4.80	$2.21 ▼ $6.64	$517.63M	0.18	1.01 million shs	909,369 shs
SAGE Sage Therapeutics	$8.69 -0.2%	$8.33	$4.62 ▼ $11.44	$543.55M	0.26	3.63 million shs	22.70 million shs

10 Stocks Set to Soar in Summer 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARVN Arvinas	-0.27%	-5.36%	-6.08%	-3.89%	-73.03%
CTNM Contineum Therapeutics	+1.02%	+3.29%	+49.00%	+45.37%	-70.29%
RZLT Rezolute	-1.34%	-6.83%	+20.78%	+46.75%	+27.75%
SAGE Sage Therapeutics	0.00%	-1.30%	-4.34%	+18.99%	-20.68%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARVN Arvinas	3.4814 of 5 stars	4.3	2.0	0.0	2.3	2.5	1.3
CTNM Contineum Therapeutics	2.5052 of 5 stars	3.6	3.0	0.0	1.1	0.8	1.3
RZLT Rezolute	2.3609 of 5 stars	3.6	1.0	0.0	1.8	4.2	0.0
SAGE Sage Therapeutics	3.738 of 5 stars	2.0	5.0	4.1	2.8	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARVN Arvinas	2.55	Moderate Buy	$20.29	173.44% Upside
CTNM Contineum Therapeutics	3.17	Buy	$22.50	277.52% Upside
RZLT Rezolute	3.14	Buy	$11.83	101.59% Upside
SAGE Sage Therapeutics	1.93	Reduce	$8.02	-7.72% Downside

Current Analyst Ratings Breakdown

Latest CTNM, ARVN, SAGE, and RZLT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/8/2025	SAGE Sage Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold	$12.00 ➝ $9.20
6/20/2025	CTNM Contineum Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform
6/20/2025	SAGE Sage Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$7.00 ➝ $9.00
6/17/2025	SAGE Sage Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold	$9.00 ➝ $8.50
6/17/2025	SAGE Sage Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Hold ➝ Hold	$8.00 ➝ $9.00
6/17/2025	SAGE Sage Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$12.00
6/17/2025	SAGE Sage Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Hold ➝ Hold	$8.00 ➝ $8.50
6/16/2025	SAGE Sage Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
6/2/2025	ARVN Arvinas	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$24.00
6/2/2025	ARVN Arvinas	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform	$10.00 ➝ $9.00
6/1/2025	ARVN Arvinas	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold

(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARVN Arvinas	$263.40M	2.06	N/A	N/A	$8.17 per share	0.91
CTNM Contineum Therapeutics	$50M	3.08	N/A	N/A	$7.66 per share	0.78
RZLT Rezolute	N/A	N/A	N/A	N/A	$2.19 per share	N/A
SAGE Sage Therapeutics	$41.24M	13.19	N/A	N/A	$5.89 per share	1.47

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARVN Arvinas	-$198.90M	-$0.66	N/A	N/A	N/A	-10.92%	-7.74%	-4.11%	8/6/2025 (Estimated)
CTNM Contineum Therapeutics	-$42.26M	-$1.97	N/A	N/A	N/A	N/A	-24.59%	-23.49%	8/12/2025 (Estimated)
RZLT Rezolute	-$68.46M	-$1.15	N/A	N/A	N/A	N/A	-70.09%	-63.08%	9/18/2025 (Estimated)
SAGE Sage Therapeutics	-$400.67M	-$4.89	N/A	N/A	N/A	-427.78%	-67.10%	-58.42%	N/A

Latest CTNM, ARVN, SAGE, and RZLT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	CTNM Contineum Therapeutics	-$0.56	N/A	N/A	N/A	$7.50 million	N/A
8/6/2025	Q2 2025	ARVN Arvinas	-$0.87	N/A	N/A	N/A	$34.42 million	N/A
7/30/2025	Q2 2025	SAGE Sage Therapeutics	-$0.96	-$0.79	+$0.17	-$0.79	$16.69 million	$31.66 million
5/14/2025	Q1 2025	CTNM Contineum Therapeutics	-$0.56	-$0.62	-$0.06	-$0.62	$7.50 million	N/A
5/13/2025	Q3 2025	RZLT Rezolute	-$0.22	-$0.27	-$0.05	-$0.27	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARVN Arvinas	N/A	N/A	N/A	N/A	N/A
CTNM Contineum Therapeutics	N/A	N/A	N/A	N/A	N/A
RZLT Rezolute	N/A	N/A	N/A	N/A	N/A
SAGE Sage Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARVN Arvinas	N/A	4.58	4.58
CTNM Contineum Therapeutics	N/A	21.47	21.47
RZLT Rezolute	N/A	8.43	8.43
SAGE Sage Therapeutics	N/A	9.16	9.13

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARVN Arvinas	95.19%
CTNM Contineum Therapeutics	N/A
RZLT Rezolute	82.97%
SAGE Sage Therapeutics	99.22%

Insider Ownership

Company	Insider Ownership
ARVN Arvinas	4.73%
CTNM Contineum Therapeutics	11.30%
RZLT Rezolute	18.39%
SAGE Sage Therapeutics	5.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARVN Arvinas	420	72.99 million	69.54 million	Optionable
CTNM Contineum Therapeutics	31	25.87 million	22.95 million	N/A
RZLT Rezolute	40	87.00 million	71.00 million	Optionable
SAGE Sage Therapeutics	690	62.62 million	59.18 million	Optionable

CTNM, ARVN, SAGE, and RZLT Headlines

Recent News About These Companies

Sage Therapeutics (NASDAQ:SAGE) Upgraded to "Hold" at Wall Street Zen

August 2 at 2:45 AM | americanbankingnews.com

Wall Street Zen Upgrades Sage Therapeutics (NASDAQ:SAGE) to Hold

August 2 at 2:44 AM | marketbeat.com

Sage (SAGE) Q2 Revenue Jumps 264%

August 1 at 3:09 PM | aol.comA

Supernus strengthens neuropsychiatric portfolio with Sage Therapeutics

August 1 at 10:08 AM | finance.yahoo.com

Sage Therapeutics, Inc. (NASDAQ:SAGE) Receives Average Rating of "Reduce" from Brokerages

July 31 at 3:19 AM | marketbeat.com

Sage Therapeutics Announces Second Quarter 2025 Financial Results

July 31 at 2:17 AM | finance.yahoo.com

Sage Therapeutics, Inc. (SAGE) Reports Q2 Loss, Beats Revenue Estimates

July 30 at 6:16 PM | zacks.com

Sage Therapeutics (NASDAQ:SAGE) Sees Strong Trading Volume - Time to Buy?

July 30 at 1:16 PM | marketbeat.com

Monaco Asset Management SAM Takes $3.51 Million Position in Sage Therapeutics, Inc. (NASDAQ:SAGE)

July 30 at 5:38 AM | marketbeat.com

Sage Therapeutics (SAGE) to Release Quarterly Earnings on Wednesday

July 28, 2025 | americanbankingnews.com

Cerity Partners LLC Purchases New Stake in Sage Therapeutics, Inc. (NASDAQ:SAGE)

July 27, 2025 | marketbeat.com

BML Capital Management LLC Buys New Shares in Sage Therapeutics, Inc. (NASDAQ:SAGE)

July 26, 2025 | marketbeat.com

Europe's CHMP gives thumbs up to Lilly's Kisunla and Gilead's long-acting PrEP drug Yeytuo

July 25, 2025 | fiercepharma.comF

Cwm LLC Acquires 58,410 Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE)

July 25, 2025 | marketbeat.com

Sage Therapeutics (SAGE) Expected to Announce Earnings on Wednesday

July 23, 2025 | marketbeat.com

Sage Therapeutics (NASDAQ:SAGE) Sees Large Volume Increase - What's Next?

July 22, 2025 | marketbeat.com

Sage Therapeutics (NASDAQ:SAGE) Shares Pass Above Fifty Day Moving Average - Should You Sell?

July 16, 2025 | marketbeat.com

SAGE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sage Therapeutics, Inc. - SAGE

July 14, 2025 | businesswire.com

Beyond The Numbers: 6 Analysts Discuss Sage Therapeutics Stock

July 9, 2025 | nasdaq.com

Scotiabank Downgrades Sage Therapeutics (SAGE)

July 9, 2025 | msn.com

Scotiabank Reiterates "Sector Perform" Rating for Sage Therapeutics (NASDAQ:SAGE)

July 8, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTNM, ARVN, SAGE, and RZLT Company Descriptions

Arvinas NASDAQ:ARVN

$7.42 -0.02 (-0.27%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$7.42 +0.00 (+0.07%)

As of 08/1/2025 06:07 PM Eastern

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.

Contineum Therapeutics NASDAQ:CTNM

$5.96 +0.06 (+1.02%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$5.96 0.00 (0.00%)

As of 08/1/2025 06:33 PM Eastern

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.

Rezolute NASDAQ:RZLT

$5.87 -0.08 (-1.34%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$5.80 -0.07 (-1.19%)

As of 08/1/2025 07:43 PM Eastern

Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

Sage Therapeutics NASDAQ:SAGE

$8.69 -0.01 (-0.16%)

Closing price 07/30/2025 07:45 PM Eastern

Extended Trading

$8.69 0.00 (0.00%)

As of 07/30/2025 07:45 PM Eastern

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression. Its product pipeline also comprises SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases; and SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington's disease, Parkinson's diseases, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. The company has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time